drugset / Trial / NCT01164488

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

NCT01164488

Phase 1 Completed 18 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This non-randomized, open-label study will evaluate the interaction of RO5190591(danoprevir)/ritonavir with and without ketoconazole and the safety and tolerability in healthy volunteers. Participants will be administered repeated daily doses of ketoconazole alone, RO5190591/ritonavir, and RO5190591/ritonavir plus ketoconazole. The anticipated time on study treatment is 25 days.

Timeline

Start
2010-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule
Subject Ritonavir Other / unclassified
Subject danoprevir Small molecule

Indications

No indication recorded.